NEW DELHI: Drug major Dr Reddy’s Laboratories on Wednesday reported a 75.92 per cent year-on-year (YoY) jump in consolidated net profit at Rs 764.2 crore for the March quarter, compared with Rs 434.4 crore in the same quarter last year.
The profit figure beat ET NOW poll estimate of Rs 506 crore.
The company reported a revenue of Rs 4,432 crore, up 10 per cent from the year-ago period.
Commenting on the results, Co-Chairman and MD, GV Prasad said: “FY 20 has been a very positive year for the company. Progress made during the year includes VAi status for CTO 6, healthy product pipeline build up, productivity improvement, and strong financial performance across our businesses.”
Ebitda margin of the company rose 60 basis points to 22.6 per cent while PAT margin leaped to 17.2 per cent from 10.8 per cent earlier.
North America remained its biggest generics market with Rs 1,807.2 crore of revenue from the region. Europe contributed with Rs 344.6 crore and India Rs 683.9 crore. Emerging markets chipped in with Rs 804.2 crore in total revenue.
Research and development spends of the company was 9.5 per cent of revenue, up from 9.1 per cent in the same period last year.